前列腺癌的 PARP 抑制剂：深陷 PROfound 和 PROpel（以及 TALAPRO-2）研究的困惑之中。
PARP Inhibitors for Prostate Cancer: Tangled up in PROfound and PROpel (and TALAPRO-2) Blues.
机构信息
The Institute of Cancer Research, London, UK; The Royal Marsden NHS Foundation Trust, Sutton, UK.
Genitourinary Oncology Service, Memorial Sloan Kettering Cancer Center, New York, NY, USA.
出版信息
Eur Urol. 2023 Sep;84(3):253-256. doi: 10.1016/j.eururo.2023.03.038. Epub 2023 Apr 20.
PMID:37087376
Abstract
The combination of PARP and androgen receptor signalling inhibitors is best reserved for cases for which we expect an overall survival benefit on the basis of disease biology. The data to date should encourage us to perform more, not less, testing for DNA repair defects.
摘要
PARP 和雄激素受体信号抑制剂的联合应用最好保留在我们预计基于疾病生物学会带来总体生存获益的情况下。目前的数据应该鼓励我们进行更多的而不是更少的 DNA 修复缺陷检测。
Zotero 插件